Allogene Therapeutics, Inc. (ALLO) income statement
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.67−0.03 (-4.17%)
Close on Nov 19, 2026Market cap $230.41MP/E –Yield 0.00%
Allogene Therapeutics, Inc. financial ratios
See a number that looks wrong?